{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:50:30Z","timestamp":1790229030212,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s15010-024-02260-7","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T09:01:54Z","timestamp":1714986114000},"page":"2207-2212","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Xpert MTB\/XDR assay: rapid TB drug resistance detection"],"prefix":"10.1007","volume":"52","author":[{"given":"Sunil","family":"Sethi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh N.","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil Kumar","family":"Dhatwalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,6]]},"reference":[{"key":"2260_CR1","unstructured":"World Health Organization. Global tuberculosis report 2023. Geneva: World Health Organization; 2023. [cited 2023]. Available from: https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports. Accessed 24 Dec 2023."},{"key":"2260_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2023.07.014","author":"I Kontsevaya","year":"2023","unstructured":"Kontsevaya I, Cabibbe AM, Cirillo DM, DiNardo AR, Frahm N, Gillespie SH. Update on the diagnosis of tuberculosis. Clin Microbiol Infect. 2023. https:\/\/doi.org\/10.1016\/j.cmi.2023.07.014.","journal-title":"Clin Microbiol Infect"},{"key":"2260_CR3","first-page":"CD009593","volume":"2","author":"JS Zifodya","year":"2021","unstructured":"Zifodya JS, Kreniske JS, Schiller I, Kohli M, Dendukuri N, Schumacher SG, et al. Xpert Ultra versus Xpert MTB\/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis. Cochrane Database Syst Rev. 2021;2:CD009593.","journal-title":"Cochrane Database Syst Rev"},{"key":"2260_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.5588\/ijtld.17.0663","volume":"22","author":"R Yadav","year":"2018","unstructured":"Yadav R, Saini A, Kaur P, Behera D, Sethi S. Diagnostic accuracy of GenoType MTBDRsl v.2.0 in detecting secondline drug resistance to M. tuberculosis. Int J Tuberc Lung Dis. 2018;22:419\u201324.","journal-title":"Int J Tuberc Lung Dis"},{"key":"2260_CR5","unstructured":"Cepheid. Xpert MTB-XDR English package insert. [Accessed 27 Sept 2021]. Available from: https:\/\/www.cepheid.com\/Package%20Insert%20Files\/Xpert%20MTB-XDR%20ENGLISH%20Package%20Insert%20302-3514%20Rev%20C.pdf"},{"key":"2260_CR6","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1128\/JCM.01771-16","volume":"55","author":"S Chakravorty","year":"2017","unstructured":"Chakravorty S, Roh SS, Glass J, Smith LE, Simmons AM, Lund K, et al. Detection of isoniazid, fluoroquinolone, amikacin, and kanamycin-resistant tuberculosis in an automated, multiplexed 10-color assay suitable for point-of-care use. J Clin Microbiol. 2017;55:183\u201398.","journal-title":"J Clin Microbiol"},{"key":"2260_CR7","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1056\/NEJMoa1614915","volume":"377","author":"YL Xie","year":"2017","unstructured":"Xie YL, Chakravorty S, Armstrong DT, Hall SL, Via LE, Songet T, et al. Evaluation of a rapid molecular drug-susceptibility test for tuberculosis. N Engl J Med. 2017;377:1043\u201354.","journal-title":"N Engl J Med"},{"key":"2260_CR8","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S1473-3099(21)00452-7","volume":"22","author":"A Penn-Nicholson","year":"2022","unstructured":"Penn-Nicholson A, Georghiou SB, Ciobanu N, Kazi M, Bhalla M, David A. Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB\/XDR assay: a cross-sectional multicentre diagnostic accuracy study. Lancet Infect Dis. 2022;22:242\u20139.","journal-title":"Lancet Infect Dis"},{"key":"2260_CR9","volume-title":"Public health mycobacteriology\u2014a guide for the level III laboratory","author":"PT Kent","year":"1985","unstructured":"Kent PT, Kubica GP. Public health mycobacteriology\u2014a guide for the level III laboratory. Atlanta: Centers for Disease Control; 1985."},{"key":"2260_CR10","volume-title":"Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. Geneva: World Health Organization; 2018."},{"key":"2260_CR11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.2991\/jegh.k.191215.003","volume":"10","author":"S Sethi","year":"2020","unstructured":"Sethi S, Agarwal P, Khaneja R, Kumar P, Kumar N, Chandna J. Second-line drug resistance characterization in Mycobacterium tuberculosis by genotype MTBDRsl assay. J Epidemiol Glob Health. 2020;10:42\u20135.","journal-title":"J Epidemiol Glob Health"},{"key":"2260_CR12","unstructured":"Global Laboratory Initiative. Line probe assays for drug resistance tuberculosis detection, interpretation, and reporting guide for laboratory staffs and clinicians. [Internet]. Available from: https:\/\/stoptb.org\/wg\/gli\/assets\/documents\/LPA_test_web_ready.pdf. Accessed 27 Dec 2023."},{"key":"2260_CR13","doi-asserted-by":"publisher","first-page":"1701354","DOI":"10.1183\/13993003.01354-2017","volume":"50","author":"P Miotto","year":"2017","unstructured":"Miotto P, Tessema B, Tagliani E, Chindelevitch L, Starks AM, Emerson C, et al. A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis. Eur Respir J. 2017;50:1701354.","journal-title":"Eur Respir J"},{"key":"2260_CR14","doi-asserted-by":"publisher","first-page":"CD014841","DOI":"10.1002\/14651858.CD014841.pub2","volume":"18","author":"S Pillay","year":"2022","unstructured":"Pillay S, Steingart KR, Davies GR, Chaplin M, De Vos M, Schumacher SG. Xpert MTB\/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin. Cochrane Database Syst Rev. 2022;18:CD014841. https:\/\/doi.org\/10.1002\/14651858.CD014841.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"2260_CR15","doi-asserted-by":"publisher","first-page":"e02314","DOI":"10.1128\/JCM.02314-20","volume":"18","author":"Y Cao","year":"2021","unstructured":"Cao Y, Parmar H, Gaur RL, Lieu D, Raghunath S, Via N. Xpert MTB\/XDR: a 10-color index assay suitable for point-of-care settings to detect isoniazid, fluoroquinolone, and second-line-injectable-drug resistance directly from mycobacterium tuberculosis-positive sputum. J Clin Microbiol. 2021;18:e02314-e2320. https:\/\/doi.org\/10.1128\/JCM.02314-20. (Print 2021 Feb 18).","journal-title":"J Clin Microbiol"},{"key":"2260_CR16","doi-asserted-by":"publisher","first-page":"e0284545","DOI":"10.1371\/journal.pone.0284545","volume":"17","author":"A Katamba","year":"2023","unstructured":"Katamba A, Ssengooba W, Sserubiri J, Semugenze D, Kasule GW, Nyombi A. Evaluation of Xpert MTB\/XDR test for susceptibility testing of Mycobacterium tuberculosis to first and second-line drugs in Uganda. PLoS ONE. 2023;17:e0284545. https:\/\/doi.org\/10.1371\/journal.pone.0284545. (eCollection 2023).","journal-title":"PLoS ONE"},{"key":"2260_CR17","doi-asserted-by":"publisher","first-page":"e0183222","DOI":"10.1128\/jcm.01832-22","volume":"20","author":"X Chen","year":"2023","unstructured":"Chen X, Li R, Ge S, Li Y, Cai C, Weng T. Rapid detection of extensive drug resistance by Xpert MTB\/XDR optimizes therapeutic decision-making in rifampin-resistant tuberculosis patients. J Clin Microbiol. 2023;20:e0183222. https:\/\/doi.org\/10.1128\/jcm.01832-22. (Epub 2023 May 30).","journal-title":"J Clin Microbiol"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-024-02260-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-024-02260-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-024-02260-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T19:02:53Z","timestamp":1733425373000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-024-02260-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,6]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2260"],"URL":"https:\/\/doi.org\/10.1007\/s15010-024-02260-7","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,6]]},"assertion":[{"value":"29 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}